Evidence map›Paper›PMID 39768310›Full record

ReviewLife (Basel, Switzerland)2024

Artificial Intelligence in the Non-Invasive Detection of Melanoma.

Banu İsmail Mendi, Kivanc Kose, Lauren Fleshner, Richard Adam, Bijan Safai, Banu Farabi, Mehmet Fatih Atak

Abstract readReview
In one paragraph

Review in Life (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Banu İsmail MendiDepartment of Dermatology, Niğde Ömer Halisdemir University, Niğde 51000, Turkey.ORCID 0000-0003-4890-1484
Kivanc KoseDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.ORCID 0000-0003-3185-2639
Lauren FleshnerSchool of Medicine, New York Medical College, Valhalla, NY 10595, USA.
Richard AdamSchool of Medicine, New York Medical College, Valhalla, NY 10595, USA.
Bijan SafaiSchool of Medicine, New York Medical College, Valhalla, NY 10595, USA.
Banu FarabiSchool of Medicine, New York Medical College, Valhalla, NY 10595, USA.ORCID 0000-0002-4748-1556
Mehmet Fatih AtakDermatology Department, NYC Health + Hospital/Metropolitan, New York, NY 10029, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
M-ISIC: A Multimodal Open-Source International Skin Imaging Collaboration Informatics Platform for Automated Skin Cancer DetectionU24CA264369 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Kivanc Kose, Veronica Miriam Rotemberg · 2022 to 2026
$3.9M
ISIC-REPO; ISIC Skin Imaging Repository Enhancements for Promoting Interoperability and UtilizationU24CA285296 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ALLAN C HALPERN, Kivanc Kose · 2024 to 2026
$2.1M
NCI NIH HHS P30 CA008748NCI NIH HHS U24 CA264369NCI NIH HHS U24 CA285296
6 · The paper itself

Abstract

Skin cancer is one of the most prevalent cancers worldwide, with increasing incidence. Skin cancer is typically classified as melanoma or non-melanoma skin cancer. Although melanoma is less common than basal or squamous cell carcinomas, it is the deadliest form of cancer, with nearly 8300 Americans expected to die from it each year. Biopsies are currently the gold standard in diagnosing melanoma; however, they can be invasive, expensive, and inaccessible to lower-income individuals. Currently, suspicious lesions are triaged with image-based technologies, such as dermoscopy and confocal microscopy. While these techniques are useful, there is wide inter-user variability and minimal training for dermatology residents on how to properly use these devices. The use of artificial intelligence (AI)-based technologies in dermatology has emerged in recent years to assist in the diagnosis of melanoma that may be more accessible to all patients and more accurate than current methods of screening. This review explores the current status of the application of AI-based algorithms in the detection of melanoma, underscoring its potential to aid dermatologists in clinical practice. We specifically focus on AI application in clinical imaging, dermoscopic evaluation, algorithms that can distinguish melanoma from non-melanoma skin cancers, and in vivo skin imaging devices.

Indexed as

algorithmsartificial intelligencedermoscopydiagnostic accuracymelanomanon-invasive skin imagingoptical coherence tomographyreflectance confocal microscopyskin cancerskin cancer detection

Identifiers

PMID39768310
PMCPMC11678477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.